(NASDAQ: INDV) Indivior Pharmaceuticals's forecast annual revenue growth rate of 4.59% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.51%.
Indivior Pharmaceuticals's revenue in 2026 is $1,332,000,000.On average, 6 Wall Street analysts forecast INDV's revenue for 2026 to be $160,616,576,289, with the lowest INDV revenue forecast at $152,473,634,508, and the highest INDV revenue forecast at $166,281,231,441. On average, 6 Wall Street analysts forecast INDV's revenue for 2027 to be $169,349,586,315, with the lowest INDV revenue forecast at $158,846,371,554, and the highest INDV revenue forecast at $176,784,446,202.
In 2028, INDV is forecast to generate $180,206,842,023 in revenue, with the lowest revenue forecast at $165,219,108,600 and the highest revenue forecast at $191,064,097,731.